Evidence map›Paper›PMID 42094336›Full record

ArticleMolecular therapy. Oncology2026

Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.

Moon Jung Choi, Eui Young So, Bedia Akosman, Young Eun Lee, Alexander G Raufi, Anthony M Reginato, Clark C Chen, Sean E Lawler, Eric T Wong, Olin D Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Moon Jung ChoiLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Eui Young SoLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Bedia AkosmanLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Young Eun LeeLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Alexander G RaufiLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Anthony M ReginatoLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Clark C ChenLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Sean E LawlerLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Eric T WongLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.
Olin D LiangLegorreta Cancer Center of Brown University, Providence, RI 02903, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent clinical trials show that CAR T cell therapies can initially blunt tumor growth in patients with glioblastoma (GBM). However, therapeutic efficacy remains limited by the immunosuppressive tumor microenvironment and restricted immune cell trafficking across the blood-brain barrier (BBB). To counteract these challenges, we have utilized the oncolytic adenovirus (OV) Ad5-Δ24-RGD as a platform to overexpress a bispecific T cell engager (BiTE) targeting both CD3 on T cells and the GBM-specific tumor associated antigen IL-13Rα2. We first demonstrated that OV-BiTE can significantly increase the recruitment of T cells to GBM, both

Indexed as

bispecific T cell engagerblood-brain barrierCAR T cellchimeric antigen receptor Tglioblastomaimmune cell engagerimmunotherapyMT: Regular Issueoncolytic adenovirusT cell recruitmenttumor microenvironment

Identifiers

PMID42094336
PMCPMC13141506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.